CDT Equity Inc. Reports $4.1 Million Net Loss in Q1 2026, Sees Significant Asset Growth

CDT Equity Inc., formerly known as Conduit Pharmaceuticals Inc., reported a net loss of $4.1 million for the first quarter of 2026, a decrease from the $4.8 million loss recorded in the same period of the previous year. The company's total operating expenses for the quarter were $3.7 million, slightly up from $3.6 million in the prior year. Research and development expenses decreased by 15% to $0.8 million, primarily due to reduced costs associated with transactions with Sarborg and other activities. General and administrative expenses rose by 7% to $2.9 million, driven by increased audit and accounting fees.

The company's financial position showed significant changes compared to the previous fiscal period. As of March 31, 2026, CDT Equity had total assets of $127.1 million, a substantial increase from $5.7 million at the end of 2025. This growth was largely attributed to the company's investment in Sarborg, which amounted to $123 million, representing a 20% equity interest. The investment was financed through the issuance of common stock and pre-funded warrants, alongside a deferred cash payment of $8 million, contingent on raising at least $20 million through an at-the-market facility program.

Operationally, CDT Equity's cash and cash equivalents decreased to $0.1 million from $1.5 million at the end of 2025. The company reported cash used in operating activities of $1.9 million for the quarter, a reduction from $3.9 million in the prior year. The decrease in cash outflow was attributed to lower net losses and adjustments for non-cash items. The company also noted a significant increase in its stockholders' equity, which rose to $105.5 million from a deficit of $7.2 million, reflecting the successful execution of its financing strategies.

Looking ahead, CDT Equity faces substantial liquidity challenges, with management expressing doubt about its ability to continue as a going concern for the next 12 months without additional funding. The company has approximately $76 million available from its at-the-market offering program but acknowledges the uncertainty surrounding its ability to raise further capital. CDT Equity plans to focus on developing clinical assets and exploring strategic partnerships to enhance its financial stability and operational capacity. The company is also actively pursuing additional relationships to license deprioritized assets, aiming to address significant health issues with unmet treatment needs.